Core Viewpoint - The company has entered into a global exclusive licensing agreement with Madrigal Pharmaceuticals for the development of six preclinical siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) [1][2] Group 1: Agreement Details - The agreement grants Madrigal exclusive global rights to utilize the company's RiboGalSTARTM and siRNA chemical modification platform for the development, production, and commercialization of several preclinical single-target and dual-target siRNA assets [1] - The company will receive an upfront payment of $60 million, with potential milestone payments totaling up to $4.4 billion, in addition to potential royalties on net sales [1] Group 2: Strategic Implications - This collaboration will leverage the company's proven liver-targeting RiboGalSTARTM platform to develop new therapies for MASH, marking a significant milestone in the company's path to becoming a leading global innovator in siRNA [2] - The partnership aims to accelerate the company's global development and commercialization strategy, addressing unmet medical needs for MASH patients with more targeted and effective therapies [2]

Core Viewpoint - Ribocure Pharmaceuticals AB, a subsidiary of Ribocure, has entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals for the development of six preclinical siRNA therapies targeting metabolic dysfunction-related fatty liver disease (MASH) [1][2] Group 1: Agreement Details - The agreement grants Madrigal exclusive global rights to utilize Ribocure's RiboGalSTAR™ and siRNA chemical modification platforms for the development, production, and commercialization of several preclinical single-target and dual-target siRNA assets [1] - Ribocure will receive an upfront payment of $60 million, with potential milestone payments totaling up to $4.4 billion, in addition to potential royalties on net sales [1] - The milestone payments are contingent upon the achievement of certain development, regulatory, and commercialization milestones, indicating uncertainty regarding the final amount Ribocure may receive [1] Group 2: Strategic Implications - This collaboration will leverage the company's proven liver-targeting RiboGalSTAR™ platform to develop new therapies for MASH, marking a significant milestone in the company's path to becoming a global leader in innovative siRNA [2] - The partnership aims to accelerate the company's global development and commercialization strategy, addressing unmet medical needs for MASH patients with more targeted and effective therapies [2]

Group 1 - The company Tianyu Biotechnology announced on February 11 that its fifth board meeting was held via telecommunication, where it reviewed the proposal to terminate the issuance of A-shares to specific targets for the fiscal year 2025 and to withdraw the application documents [1] - The decision to withdraw the application indicates a strategic shift in the company's funding approach, potentially impacting its future capital structure and investment plans [1] Group 2 - The news highlights a significant development in the film industry, where a new Chinese video model is generating 15-second videos from dozens of prompts, leading to a surge in stock prices for film-related companies [1] - This advancement in video generation technology is being referred to as the "strongest on earth," suggesting a competitive edge for companies involved in this sector [1]

Core Viewpoint - The company, Junshi Biosciences, has announced the completion of the first patient dosing in a 1b/2 clinical study of HLX43 in combination with HLX07 or Hansizhuang for patients with advanced or metastatic colorectal cancer in mainland China [1][2] Group 1 - The study aims to evaluate the safety, tolerability, and efficacy of HLX43 combined with HLX07 or Hansizhuang in patients with advanced or metastatic colorectal cancer [2] - The study consists of two parts: the first part includes a safety lead-in phase and a dose expansion phase, utilizing a 3+3 dose escalation design [2] - The primary objective of the first phase is to assess the safety and tolerability of different dose levels of HLX43 combined with HLX07, while secondary objectives include pharmacokinetics, immunogenicity, efficacy, and potential biomarkers [2] Group 2 - The second phase is a randomized, multi-center, open-label study evaluating HLX43 at two dose levels combined with fixed-dose HLX07, focusing on efficacy in metastatic colorectal cancer patients [2] - The secondary objectives of the second phase include evaluating safety and tolerability, pharmacokinetics, immunogenicity, and potential predictive or resistance biomarkers [2] - Additionally, the second part assesses HLX43 combined with fixed-dose Hansizhuang in metastatic colorectal cancer patients, with similar objectives regarding efficacy and safety [2]

Core Viewpoint - The announcement from Junshi Biosciences (复宏汉霖) indicates the initiation of a clinical study for HLX43 in combination with HLX07 or Hansizhuang (汉斯状®) for patients with advanced or metastatic colorectal cancer in mainland China [1] Group 1 - Junshi Biosciences has completed the first patient dosing in a 1b/2 phase clinical study for HLX43, a PD-L1 targeted antibody-drug conjugate [1] - The study involves the combination of HLX43 with HLX07, a recombinant humanized monoclonal antibody injection targeting EGFR, or Hansizhuang, a monoclonal antibody injection [1] - The clinical research is being conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 注射用HLX43（靶向PD-L1抗體偶聯藥物） 聯合HLX07（重組抗EGFR人源化單克隆抗體注射液） 或漢斯狀® （斯魯利單抗注射液） 在晚期或轉移性結直腸癌患者中開展的1b/2期臨床研究 於中國境內完成首例患者給藥 A. 緒言 1 料，暫定HLX43的劑量水準為2.5 mg/kg和3.0 mg/kg，該階段主要目的是研究不 同劑量HLX43聯合固定劑量HLX07在轉移性結直腸癌(mCRC)患者中的有效性， 次要目的包括評價其安全性和耐受性、HLX43的PK特徵和免疫原性、並研究潛在 預測性或耐藥性生物標誌物。第二部分為一項隨機、多中心、開放標籤研究，評 估HLX43 2.0 mg/kg或2.5 mg/kg聯合固定劑量漢斯狀®(30 ...

Core Viewpoint - The company is effectively managing its production capacity to meet market demand for its products, particularly in the field of calcium silicate bioceramics for dental bone repair [2]. Group 1: Production Capacity - The company reported that its overall production capacity is operating within a normal and efficient range, responding to customer order demands [2]. - A dedicated production line for calcium silicate bioceramics has been established prior to product certification and market launch, ensuring stable and efficient production [2]. Group 2: Market Demand - The production capacity of the new product line is sufficient to meet the anticipated market demand for calcium silicate bioceramics [2].

Group 1 - The core point of the news is that Junshi Biosciences (688180.SH) is currently experiencing a decline in stock price, closing at 35.03 yuan with a drop of 1.93% [1] - Junshi Biosciences was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share [1] - The stock reached its highest point at 220.40 yuan on the first day of trading but is now in a state of decline [1] Group 2 - In 2020, Junshi Biosciences raised a total of 4.836 billion yuan from its initial public offering, with a net amount of 4.497 billion yuan after deducting issuance costs [1] - The company initially planned to raise 2.7 billion yuan, which was exceeded by 1.797 billion yuan [1] - The total fundraising amount from the company's specific issuance of A-shares in 2022 was approximately 3.7765 billion yuan, with a net amount of about 3.7448 billion yuan after fees [2] - The total amount raised by Junshi Biosciences from both fundraising rounds is 8.612 billion yuan [2]

Core Viewpoint - The company, CanSino Biologics, is expected to turn a profit in 2025, with significant advancements in vaccine development and ongoing expansion into international markets [1][2]. Financial Performance - The company forecasts revenue between 1.04 billion to 1.08 billion yuan for 2025, representing a year-on-year growth of 22.88% to 27.61%. Net profit attributable to shareholders is projected to be between 24.5 million to 29 million yuan, indicating a turnaround from previous losses. The audited annual report is scheduled for release in 2026 [2]. Product Development Progress - The self-developed DTPa vaccine has completed Phase III clinical trials and is expected to receive market approval in the first half of 2026, potentially replacing imported products and expanding into the high-end vaccine market. The 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) has been approved for clinical trials by the National Medical Products Administration of China, marking it as the first 24-valent pneumonia vaccine to enter clinical trials globally [3]. Business Expansion - The company is actively expanding into overseas markets in Southeast Asia, the Middle East, North Africa, and South America. For instance, the Manhaixin vaccine has received halal certification in Indonesia and has begun exports, with potential for deeper local partnerships and technology transfers [4]. Future Development - Other research pipeline updates include the prioritization of the DTPa vaccine for infants, acceptance of the application for the Tetanus vaccine, and international support for the recombinant poliovirus vaccine (VLP-Polio). The clinical and approval progress of these products may significantly impact the company's long-term development [5].

Group 1 - The core viewpoint of the news is that Hualan Vaccine's stock has experienced a decline, with a drop of 1.25% to 21.34 CNY per share, resulting in a total market capitalization of 12.826 billion CNY and a cumulative decline of 5.91% over four consecutive days [1] - Hualan Biological Vaccine Co., Ltd. is located in Xinxiang City, Henan Province, and was established on November 9, 2005. The company was listed on February 18, 2022, and its main business involves the research, production, and sales of human vaccines, with 98.11% of its revenue coming from vaccine products [1] Group 2 - From the perspective of Hualan Vaccine's top ten circulating shareholders, a fund under Southern Fund is among them. The Southern CSI 1000 ETF (512100) reduced its holdings by 8,700 shares in the third quarter, holding 1.6522 million shares, which accounts for 0.28% of the circulating shares [2] - The Southern CSI 1000 ETF (512100) has a current scale of 78.996 billion CNY and has reported a year-to-date return of 8.61%, ranking 1564 out of 5569 in its category. Over the past year, it has achieved a return of 34.61%, ranking 1862 out of 4295 [2] - The fund manager of Southern CSI 1000 ETF (512100) is Cui Lei, who has been in the position for 7 years and 98 days, with a total asset scale of 137.02 billion CNY. During this period, the best fund return was 251.88%, while the worst was -15.93% [2]